Early Immunogenicity Risk Mitigation
Poster Sep 10, 2014
Chloé Ackaert, Brecht Hoedemaekers, Sofie Pattijn and Philippe Stas
The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems.
Implementing early immunogenicity assessment strategies using tools like in silico T cell epitope prediction and in vitro T cell assays can contribute significantly to the successful outcome of drug development programs and reduce the number of product failures.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE